PPT-Switch to LPV/

r 3TC OLE Study LPV r bid 3TC or FTC qd NRTI N 127 N 123 LPV r bid 3TCFTC qd Design Randomisation 1 1 Openlabel Objective Primary Endpoint proportion without treatment failure at W48 . A and then SWITCH SIDESCCDC B Switch sides after points1,5,9,13,17, for . treatment monitoring. Nathan . Ford. Dept. of . HIV/AIDS. World Health . Organization. WHO ART guidelines evolution. Topic. 2002. 2003. 2006. 2010. 2013. When to start. CD4 ≤200. CD4 ≤ 200. Localizer Performance without Vertical Guidance (LP) and Lateral Navigation (LNAV)LPs are non-precision approaches with WAAS lateral guidance. They are added in locations where terrain or obstructions 2013. What do we use electricity for?. Where does electricity come from?. How can we save electricity at home and at school?. Save money for your family and . save your planet. Make the pledge and switch off. M Harris, . S Guillemi. , K Chan, B Yip. ,. . M Hull, V Dias Lima, R Hogg, J . Montaner. Abstract #: WEAB0202. Organ Dysfunction in HIV: It's . Complicated. Wednesday, 3 July 2013 14:30-16:. 00. Session . STRIIVING . Study. Design. Endpoints. Primary: proportion of patients maintaining HIV RNA < 50 c/mL at W48 . (ITT-E, snapshot) ; non-inferiority if lower margin of the two-sided 95% CI . for the difference = - 10%, 90% power . Planning and . Implementation. July 2015. 1. Contents. Polio Endgame Objective 2. Rationale for switching from tOPV to bOPV. Dates and timelines around the Switch. Guidance for implementation:. Plan. . Easier for HCW’s to prescribe for . all. ages. Easier for caregivers to administer to infants . and children. Easier for infants and children to adhere. Easier to manage supply chain. Target Product Profile for . SPARE . Study. SPARE Study: switch to DRV/r + RAL . Design. Age ≥ . 20. years. HIV+. HIV-1 RNA. < 50 c/ml > 15 weeks. On LPV/r + TDF/FTC. No prior . virologic. failure. on PI/r- or INSTI-containing regimen. implementation of Dolutegravir. Meireles MV. , Pascom ARP, Perini F, Rick F, Benzaken A. . Ministry of Health of Brazil, Department of STI, AIDS and Viral Hepatitis. Acknowledgements. No. . conflicts of interest. LPV/r mono vs LPV/r ZDV/3TC MONARK. LPV/r QD vs BID. . M02-418. . M05-730. . A5073. LPV/r 3TC vs LPV/r 2 NRTI GARDEL. ATV/r vs FPV/r ALERT. ATV/r vs DRV/r ATADAR. FPV/r vs LPV/r KLEAN. Switch to LPV/r + RAL KITE Study KITE Study: switch to LPV/r + RAL Design Age ≥ 18 years HIV+ No previous virologi c failure to PI/r-based ART HIV-1 RNA < 50 c/ml On stable (≥ 6 months) 2 NRTI + 3rd agent Dr Laura Oyiengo. NATIONAL AIDS STI CONTROL PROGRAM. MOH. BACKGROUND. As a country with the fourth largest Pediatric HIV epidemic in the world, Pediatricians need to be involved in programming, decision making and management of children and adolescent living with HIV and also in PMTCT programming.. by Baseline NRTI Resistance . and Second-Line NRTI Use. Dannae. Brown,. 1. . Ruolan. Wang,. 2. Mark Underwood,. 2. Judy Hopking,. 3. Maria Claudia Nascimento,. 4. . Michael Aboud,. 4. . Jörg.